Valuation
- Market cap
- 95,332,000
- Revenue TTM
- $0
- Net income TTM
- $-59,520,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 243,797
- Avg volume
- 281,476
- Day's range
- $2.28 – $2.59
- Shares out
- 40,395,000
- Stochastic %K
- 62%
- Beta
- 0.12
- Analysts
- Strong Sell
- Price target
- $15.50
Company profile
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, in...
Show more
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 720-307-2892
- Website
- https://onkuretherapeutics.com
- Address
- 6707 Winchester Circle, Suite 400, Boulder, United States
Latest news
No headlines yet.
